Edition:
India

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

5.42CAD
19 Jul 2019
Change (% chg)

$-0.23 (-4.07%)
Prev Close
$5.65
Open
$5.56
Day's High
$5.65
Day's Low
$5.40
Volume
76,788
Avg. Vol
135,710
52-wk High
$11.45
52-wk Low
$5.17

Latest Key Developments (Source: Significant Developments)

Theratechnologies - European Medicine Agency Grants Theratechnologies An Additional Month To Complete Responses Related To Trogarzo Application
Friday, 24 May 2019 

May 24 (Reuters) - Theratechnologies Inc ::EUROPEAN MEDICINE AGENCY GRANTS THERATECHNOLOGIES AN ADDITIONAL MONTH TO COMPLETE RESPONSES RELATED TO TROGARZO® APPLICATION.THERATECHNOLOGIES INC - ASSUMING A POSITIVE CHMP OPINION, PLANS TO LAUNCH IN GERMANY BEFORE END OF YEAR REMAIN UNCHANGED..THERATECHNOLOGIES INC - WILL SUBMIT RESPONSES TO EMA BY END OF JUNE 2019.THERATECHNOLOGIES - GOT MORE TIME TO ADDRESS NEW QUESTIONS IN REGARD TO ESTABLISHMENT OF REGISTRY TO GATHER LONG-TERM DATA ON PATIENTS TAKING TROGARZO.  Full Article

Theratechnologies Q4 Loss Per Share C$0.02
Thursday, 21 Feb 2019 

Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2018.Q4 REVENUE C$18.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF C$19.8 MILLION.Q4 LOSS PER SHARE C$0.02.Q4 EARNINGS PER SHARE ESTIMATE C$0.00 -- REFINITIV IBES DATA.  Full Article

Trogarzo Phase III Data Analysis Presented At HIV Drug Therapy Glasgow 2018
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Theratechnologies Inc ::TROGARZO® PHASE III DATA ANALYSIS PRESENTED AT HIV DRUG THERAPY GLASGOW 2018: PATIENTS NOT ACHIEVING PRIMARY ENDPOINT AT DAY 7 EXPERIENCED CLINICAL BENEFIT BY END OF STUDY.THERATECHNOLOGIES INC - OF 40 PATIENTS ENROLLED IN PHASE III CLINICAL TRIAL, ONLY SEVEN DID NOT ACHIEVE PRIMARY ENDPOINT..THERATECHNOLOGIES INC - PATIENTS IN THE STUDY WHO DID NOT ACHIEVE PRIMARY ENDPOINT EVENTUALLY DID EXPERIENCE CLINICAL BENEFITS DURING STUDY..  Full Article

Theratechnologies Reports Q3 Earnings Per Share C$0.00
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018.Q3 EARNINGS PER SHARE C$0.00.Q3 REVENUE C$17.71 MILLION VERSUS I/B/E/S VIEW C$16.8 MILLION.Q3 EARNINGS PER SHARE VIEW C$-0.01 -- THOMSON REUTERS I/B/E/S.  Full Article

Theratechnologies Q3 Loss Per Share C$0.04
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018.Q3 LOSS PER SHARE C$0.04.Q3 REVENUE C$17.71 MILLION VERSUS I/B/E/S VIEW C$16.8 MILLION.Q3 EARNINGS PER SHARE VIEW C$-0.01 -- THOMSON REUTERS I/B/E/S.  Full Article

Theratechnologies Q2 Loss Per Share C$0.03
Thursday, 5 Jul 2018 

July 5 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 SALES ROSE 23.1 PERCENT TO C$12.3 MILLION.Q2 LOSS PER SHARE C$0.03.  Full Article

Theratechnologies Submits Novel Single-Vial Formulation Of Egrifta For FDA Approval
Wednesday, 4 Jul 2018 

July 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES SUBMITS NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA® (TESAMORELIN FOR INJECTION) FOR FDA APPROVAL.THERATECHNOLOGIES INC - FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH FDA FOR A SINGLE-VIAL FORMULATION OF EGRIFTA.  Full Article

Theratechnologies Announces US$50 Mln Bought Deal Offering Of Certain Notes
Thursday, 31 May 2018 

May 30 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES US$50 MILLION BOUGHT DEAL OFFERING OF 5.75% CONVERTIBLE UNSECURED SENIOR NOTES.THERATECHNOLOGIES - INTENDS TO USE PROCEEDS OF OFFERING TO FUND PAYMENTS DUE UNDER AMENDMENT OF EMD SERONO TERMINATION AGREEMENT.  Full Article

FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA
Tuesday, 1 May 2018 

May 1 (Reuters) - Theratechnologies Inc ::FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION).THERATECHNOLOGIES - FDA DETERMINED LARGE-SCALE POST-APPROVAL TRIALS NO LONGER REQUIRED AS CURRENT LABELING ADEQUATELY REFLECTS SAFETY PROFILE OF EGRIFTA.THERATECHNOLOGIES - FOR YEAR ENDED NOV 30, 2017, CO ESTIMATED POST-APPROVAL COMMITMENTS WILL REQUIRE $13 MILLION INVESTMENT, WHICH WILL NO LONGER BE NEEDED.  Full Article

Theratechnologies Reports Q1 Loss Per Share C$0.04
Thursday, 5 Apr 2018 

April 5 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 2018.THERATECHNOLOGIES INC <<>> Q1 REVENUE C$10.22 MLN VS I/B/E/S VIEW C$10.7 MLN.THERATECHNOLOGIES INC <<>> Q1 SHR LOSS C$0.04.THERATECHNOLOGIES - AS AT FEB 28, CASH, BONDS AND MONEY MARKET FUNDS AMOUNTED TO $32.5 MLN COMPARED TO $32.9 MLN AT END OF PREVIOUS FISCAL YEAR.  Full Article